Kornimate/medical-research-clean huggingface dataset:
imaging-based deep learning for lung cancer diagnosis and staging

Conditions: Lung Cancer

Summary: lung cancer diagnosis and staging are two fundamental and critical issue in clinical lung cancer management and therapeutic decision-making. invasive procedures for pathologic analysis are gold standard for diagnosis and staging, however, invasive procedures related-complications are inevitable. noninvasive medical imaging is a powerful tool, however there is almost no room for improvement just according to the experience of radiologist and clinician. the researchers will investigate the role of computer based deep learning of medical imaging in the diagnosis of lesion of lung, lymph node and other sites suspected with metastasis.

radiologist

Eligibility criteria:
inclusion criteria: * pathological diagnosis of lung cancer * pet/ct or ct examination before any cancer-specific treatment exclusion criteria: * a history of other malignancies
a study to evaluate effectiveness and safety of deucravacitinib in participants with non-pustular palmoplantar and genital psoriasis

Conditions: Palmoplantar Psoriasis; Genital Psoriasis

Summary: the purpose of this study is to measure the safety and effectiveness of deucravatinib in participants with non-pustular palmoplantar psoriasis and genital psoriasis.


Eligibility criteria:
key inclusion criteria: inclusion criteria for non-pustular palmoplantar psoriasis * men and women diagnosed with stable plaque psoriasis with involvement of the palm(s)and/or sole(s) for at least 6 months or more. stable psoriasis is defined as no morphology changes or significant flares of disease activity in the opinion of the investigator. * moderate-to-severe plaque psoriasis defined as s-pga score of ≥ 3 on a 5-point scale at both screening visit and day 1. * moderate-to-severe non-pustular pp psoriasis, defined as pp-pga score of ≥ 3 on a 5-pointscale and pp-pasi ≥ 8 at both screening visit and day 1. * a total maximum of 5 sterile pustules across both palms and soles limited only to psoriatic plaques will be allowed. * evidence of typical plaque psoriasis outside palms and soles at both screening visit and day 1. * deemed by the investigator to be a candidate for phototherapy or systemic therapy. * failed to respond to, or intolerant of ≥ 1 topical therapy. inclusion criteria for genital psoriasis * men and women diagnosed with stable plaque psoriasis with involvement of the genital area for at least 6 months or more. stable psoriasis is defined as no morphology changes or significant flares of disease activity in the opinion of the investigator. * moderate-to-severe plaque psoriasis defined as s-pga score of ≥ 3 on a 5-point scale at both screening visit and day 1. * moderate-to-severe genps, defined as static physician's global assessment of genitalia (s-pga-g) score of ≥ 3 on a 6-point scale at both screening visit and day 1. * evidence of typical plaque psoriasis in a non-genital area at both screening visit and day 1. * deemed by the investigator to be a candidate for phototherapy or systemic therapy. * failed to respond to, or intolerant of ≥ 1 topical therapy. key exclusion criteria: target disease exceptions * has non-plaque psoriasis (for pp pustulosis, pp pustular psoriasis, isolated pustules on palms or soles with or without erythema outside psoriatic plaques, guttate, pustular, erythrodermic, and drug-induced psoriasis) at screening or day 1. other protocol-defined inclusion/exclusion criteria apply.

Keywords: deucravacitinib bms-986165 sotyktu plaque psoriasis
control of pain from braces with patient advice sheets

Conditions: Orthodontic Appliance Complication

Summary: to compare the analgesic property of acupressure with nsaids (ibuprofen) in controlling pain following orthodontic treatment. this will be achieved by assessing the effectiveness of acupressure in controlling pain and discomfort by measuring the degree of pain relief after bonding of brackets to teeth and placement of initial archwire.

single centred randomised controlled trial with subjects recruited from a hospital orthodontic outpatient department in dundee dental hospital. if informed consent is obtained, then the subject details will be delivered to the trial coordinator for randomisation to one of the groups, nsaids or acupressure group. all subjects who are eligible for inclusion will be advised of the nature and purpose of the trial. the total number of subjects recruited will be approximately 36 with the acupressure and nsaid group containing approximately 18 subjects each. all subjects who meet the inclusion criteria will be informed of the study and written consent sought for their participation. subjects will be recruited from the new patient clinics and routine treatment waiting list. . the subjects will be asked to measure the level and duration of pain and discomfort using a pain diary to record their experiences using visual analogue scales (vas). the pain diary will be completed from 4 hours to 7 days after treatment after the insertion of the first orthodontic aligning archwire. intervention groups in the acupressure group the subjects will be given an advice sheet and advised to use a definitive acupressure point on the back of the hand region to control orthodontic pain. in the nsaid group the subjects will be given an advice sheet and advised to take ibuprofen for the orthodontic pain pain scores via vas will be analysed at 4hours, 24 hours, and 7 days after the orthodontic treatment. the vas consists of a horizontal line, 100 mm in length with descriptive words at each end of the line which act as anchors e.g. no pain, great pain. the patient marks on the line the point that they feel represents their perception of their current state. the vas score is determined by measuring in millimetres from the left hand end of the line to the point that the patient marks

Eligibility criteria:
inclusion criteria: * aged 12-25 * malocclusion requiring treatment * scheduled to begin orthodontic treatment * requires fixed orthodontic braces on upper and lower teeth. exclusion criteria: * previous orthodontic treatment * current use of analgesics * contraindications to the use of nsaids * previous acupressure experience * pregnant

Keywords: pain
gaba and beta-cell regeneration

Conditions: Diabetes Mellitus, Type 1

Summary: gaba(gamma-aminobutyric acid) may be used for decreasing anti-gad antibodies and leads beta-cell regeneration.

100 patients with type i diabetes were in 2 groups, had been monitored in a private clinic, number 50 each group, with 30 females and 20 males after the written consent of all patients. all the patients lied between 18-25 years old with 5-10 years of diabetes onset. the first group was on insulin therapy in the form of toujeo once daily and novorapid 3 times daily and they received gaba nutritional supplement 750mg per day. the second group was only on insulin injection in the form of toujeo once daily and novorapid 3 times daily. in the first group;the investigator measured fasting c peptide levels before and after 6 months of gaba 750mg daily.also,the investigator measured anti gad antibodies before and after 6 months of treatment. in the second group,the investigator measured c peptide levels and anti-gad antibodies at the beginning of the trial and after 6 months.

Eligibility criteria:
inclusion criteria: - type 1 diabetes patients age from 18 to 25 years on basal bolus insulin exclusion criteria: thyroid problems liver disease kidney disease

Keywords: type 1diabetes, gaba
evaluation of headache and childbirth in a chronic pain population

Conditions: Headache

Summary: headache and backache are common symptoms following childbirth. the incidence of these symptoms have been shown to increase during the postpartum period between 5 to 12 months following delivery. by 12 months postpartum up to 45% and 65% of women experience headache and backache, respectively. while studies have reported headache and backache as frequently persistent symptoms beyond the first year postpartum, few studies have specifically interrogated women seeking specialist pain physician input or identified predisposing risk factors. finally there is little known about typically described pain characteristics of women who suffer with chronic postpartum headache and backache. we aim to compare the prevalence of chronic headache in women that have versus have not experienced childbirth.


Eligibility criteria:
inclusion criteria: * women greater than 18 years old * agreeing to be contacted for research purposes. * able to read and understand english who have had agreed to be contacted with a valid email address exclusion criteria: * self identified as non-female * age \<18 years old. * women without computer or electronic device access or valid email address and women who did not respond
does human skeletal muscle possess an epigenetic memory of testosterone?

Conditions: Healthy Aging; Age-Related Sarcopenia; Testosterone Deficiency

Summary: this project's primary aim of this double-blinded, randomised, placebo-controlled trial is to investigate whether short-term testosterone administration +/- resistance exercise training induces a muscle memory response that can lead to longer-lasting benefits in aged human skeletal muscle. the investigators will provide older men with the anabolic hormone, testosterone or placebo, with or without resistance training, followed by a period of testosterone abstinence and detraining, followed by a subsequent repeated period of resistance training (retraining). this will help determine if earlier encounters with short-term testosterone administration can be "remembered" and if adaptation to later retraining can be enhanced as a consequence of encountering testosterone earlier.


Eligibility criteria:
inclusion criteria: * sedentary males * 55-70 years old * serum testosterone levels \>8 nmol/l measured in the morning * without any known illness, disease or other conditions * undergone screening through medical questionnaire, physical examination, routine blood tests and urine sample * written informed consent received exclusion criteria: * current or previous participation in a formal exercise regime * a bmi \ 30 kg·m2 * hypersensitivity to the study drug or to any of its constituents * active cardiovascular disease: uncontrolled hypertension (bp \> 160/100 mmhg), angina, heart failure (class iii/iv), arrhythmia, right to left cardiac shunt, recent cardiac event * family history of early (\<55y) death from cardiovascular disease * haematocrit \>50% * malignancy * prostate-specific antigen (psa) \>4 ng/ml * lower urinary tract symptoms * taking beta-adrenergic blocking agents, statins, non-steroidal anti-inflammatory drugs * cerebrovascular disease: previous stroke, aneurysm (large vessel or intracranial), epilepsy * respiratory diseases including: pulmonary hypertension, chronic obstructive pulmanary disease (copd), asthma, sleep apnoea * metabolic disease: hyper and hypo parathyroidism, untreated hyper and hypothyroidism, cushing's disease, type 1 or 2 diabetes * active inflammatory bowel or renal disease * current or previous steroid treatment or hormone replacement therapy * clotting dysfunction * musculoskeletal or neurological disorders * alcohol or drug abuse * receiving oral anticoagulants * serum testosterone levels above the reference range for 50 year olds (\>32 nmol/l) (bjerner et al., 2009) measured in the morning 1

Keywords: healthy aging preventing age-related sarcopenia overcoming anabolic resistance anti-doping
improving the quality of anesthesia induction by reducing preoperative anxiety in the operating room

Conditions: Anxiety at Induction of Pediatric Anesthesia

Summary: preoperative anxiety refers to a range of physical and/or psychological manifestations, which can have a significant impact on medical outcomes and the experience of the child and their parents. this study aims to evaluate the impact of preoperative preparation combined with a hypnosis session conducted by nurse anesthetists (iade) trained in working with children and their families. the goal is to improve the child's experience and reduce perioperative anxiety and stress. it is divided into two phases: * first phase, called "before": standard preoperative care is provided according to the existing protocol in the department. anxiety levels will be measured at the time of induction in the operating room. * second phase, called "after": in the two weeks prior to surgery, in addition to the standard preoperative care currently in place, the patient will receive a 30-minute visit from a nurse anesthetist trained in hypnosis. this is an added procedure complementing the anesthesia consultation. the visit is divided into two parts: 10 minutes to review and clarify the explanations given by the anesthesiologist and surgeon, and 20 minutes of a formal hypnosis session. a personalized liaison form will be completed to facilitate communication between the consultation and the operating room. anxiety levels will again be measured at the time of induction.


Eligibility criteria:
inclusion criteria: * children aged between 5 and 12 years, i.e., able to engage in verbal communication; * scheduled for surgery requiring hospitalization at least one day prior to the procedure, including but not limited to gastrointestinal or urological surgery, ent procedures, plastic interventions, and orthopedic surgery (e.g., scoliosis correction); * provision of written informed consent by the parents or legal guardians (or by the sole parent/legal guardian, where applicable); * parental agreement to participate in the study by completing the required questionnaires;affiliation with or entitlement to a national social security scheme exclusion criteria: * patients with cognitive developmental disorders; * patients requiring regular general anesthesia as part of ongoing medical management; * patients undergoing emergency surgery; * patients with a known psychiatric disorder; * patients diagnosed with an autism spectrum disorder (asd).

Keywords: anxiety at induction preoperative anxiety
neuroimaging in healthy aging and senile dementia (hasd_ind)

Conditions: Alzheimer Disease

Summary: to identify factors that signal the transition from asymptomatic (preclinical) to symptomatic alzheimer disease (ad).

the purpose of this research study is to evaluate the structure and function of the brain in healthy aging and early alzheimer's disease using positron emission tomography (pet), magnetic resonance imaging (mri), and computed tomography (ct) imaging. the study involves imaging the brain to detect the presence of amyloid deposits (plaques in the brain). amyloid is a protein that may be related to dementia of alzheimer's disease (dat). this study will use radioactive tracers called c-11 pittsburgh compound b (pib) and f 18/ av-1451 (flortaucipir) which binds to beta amyloid and tau in the brain. these compounds are considered investigational, which means that they have not been approved by the united states food and drug administration (fda).

Eligibility criteria:
inclusion criteria: * male or female, any race * age \> 18 years * participation in one of the ongoing projects affiliated with the knight adrc at washington university and referred by the map staff and a washington university physician. * normal cognition or early-stage symptomatic ad * willing and able to undergo study procedures. * capacity to give informed consent and follow study procedures exclusion criteria: * has any condition that, in the investigator's opinion, could increase risk to the participant, limit the participant's ability to tolerate the research procedures, or interfere with the collection/analysis of the data (e.g., participants with severe chronic back pain might not be able to lie still during the scanning procedures); * has hypersensitivity to either av-1451 or pib or any of its excipients; * contraindications to pet, ct or mri (e.g. electronic medical devices, inability to lie still for extended periods) that make it unsafe for the individual to participate; * severe claustrophobia; * currently pregnant or breast-feeding. women must agree to avoid becoming pregnant and must agree to refrain from sexual activity or to use reliable contraceptive methods for 24 hours following administration of flortaucipir injection; * must not have participated in any clinical trial involving a study drug or device within the 30-days prior to study enrollment; * must not participate in another drug or device study prior to the end of this study participation; * current or recent (within 12 months prior to screening) participation in research studies involving radioactive agents such that the total research-related radiation dose to the participant in any given year would exceed the limits set forth in the u.s. code of federal regulations (cfr) title 21 section 361.1. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=361.1

Keywords: dementia neuro-degenerative disease amyloid plaque mild cognitive impairment brain disease
efficacy of gabapentin or amitriptyline to reduce postoperative pain after lumbar laminectomy and diskectomy

Conditions: Herniated Disc; Intervertebral Disc Displacement

Summary: the hypothesis of this study is that gabapentin or amitriptyline has no role in preemptive analgesia to reduce postoperative pain after lumbar diskectomies.

pain suppression plays a decisive role in patients' satisfaction following lumbar diskectomies, as the psychological component of the pain is a major cause of treatment failure. controversy exists whether preemptive prescription of gabapentin, as a known contributor to reduce postoperative pain, has a role in patients undergoing laminectomy for lumbar diskectomy or spinal canal stenosis.the aim of this study is to test the efficacy of amitriptyline and gabapentin in this group of neurosurgical patients.

Eligibility criteria:
inclusion criteria: * signed informed consent * age:18 to 60 * weight: 60 to 80 kg * asa class: i,ii * concordant physical and imaging findings in favor of symptomatic lumbar disk herniation * single level lumbar disk herniation unresponsive to medical treatment exclusion criteria: * previous consumption of gabapentin or amitriptyline * known allergy to investigated drugs * reluctant to sign informed consent * previous history of intolerance to narcotics * simultaneous lumbar diskectomy and a fusion technique * known renal failure * pregnancy * contraindications to amitriptyline or gabapentin prescription * unable to use pca * habitual use of alcohol or opium * history of analgesic consumption during the last 24hours

Keywords: lumbar diskectomy laminectomy
phase 1b multi-indication study of anetumab ravtansine in mesothelin expressing advanced solid tumors

Conditions: Neoplasms

Summary: the key purpose of the main part of the study is to assess efficacy and safety of anetumab ravtansine as monotherapy or combination therapy for mesothelin expressing advanced solid tumors. the main purpose of the safety lead-in (dose-finding) part of the study is to determine the safety and tolerability of anetumab ravtansine in combination with cisplatin and in combination with gemcitabine, and to determine the mtd of anetumab ravtansine in combination with cisplatin for mesothelin expressing advanced cholangiocarcinoma and in combination with gemcitabine for mesothelin expressing advanced adenocarcinoma of the pancreas. patients will receive anetumab ravtansine every three weeks in monotherapy for most indications. in cholangiocarinoma and adenocarinoma of the pancreas, 3-weekly anetumab ravtansine is administered in combination with cisplatin or gemcitabine respectively (both administered in a 2 week on / 1 week off schedule). treatment will continue until disease progression or until another criterion for withdrawal is met. .efficacy will be measured by evaluating the tumor's objective response rate. radiological tumor assessments will be performed at defined time points until the patient's disease progresses. blood samples will be collected for safety, pharmacokinetic and biomarker analysis. archival or fresh biopsy tissue will also be collected for mesothelin expression testing and biomarker analyses.


Eligibility criteria:
inclusion criteria: * availability of tumor tissue for mesothelin expression testing and for further biomarker analysis * histologically-confirmed, mesothelin-expressing metastatic or advanced non-metastatic disease (tumour type specific inclusion criteria) * at least one measurable lesion according to response evaluation criteria in solid tumors (recist 1.1) (or for thymic carcinoma, at least one measurable lesion per international thymic malignancy interest group (itmig) modified recist 1.1 criteria * adequate bone marrow, liver, renal and coagulation function * left ventricular ejection fraction (lvef) ≥ 50% of the lower limit of normal (lln) according to local institutional ranges * eastern cooperative oncology group (ecog) 0 or 1 exclusion criteria: * exposure to more than one prior anti-tubulin/microtubule agent * corneal epitheliopathy or any eye disorder that may predispose the patients to this condition * symptomatic central nervous system (cns) metastases and/or carcinomatous meningitis * contraindication to both ct and mri contrast agents * active hepatitis b or c infection * pregnant or breast-feeding patients * tumor type specific exclusion criteria

Keywords: cholangiocarcinoma pancreatic cancer triple-negative breast cancer non-small cell lung cancer thymic carcinoma gastric including gastroesophageal junction cancer
pulseselect™ pfa global registry

Conditions: Atrial Fibrillation

Summary: the pulseselect™ pfa global registry is a prospective, global, multi-center, observational post-approval study. subjects will be treated with the pulseselect™ pfa system and followed according to soc.

the pulseselect™ pfa global registry is a prospective, global, multi-center, observational post-market registry. the purpose of this clinical study is to collect clinical performance and safety data in a broad patient population treated with the pulseselect™ pfa system. the pulseselect™ pfa system used in the study is market approved. the ablation procedure will be performed according to routine hospital practice. the follow up period is intended to align with standard practice and subjects will be followed for a minimum of 12 months post-procedure.

Eligibility criteria:
inclusion criteria: * subject is ≥ 18 years of age or minimum age as required by local regulations. * subject has been diagnosed with atrial fibrillation (af) * planned procedure using commercially available pulseselect™ pfa system. * willing to comply with study requirements and give informed consent (defined as legally effective, documented confirmation of a subject's voluntary agreement to participate in this clinical study) or authorization per institution and geographical requirements. exclusion criteria: * subject is enrolled in a concurrent study that has not been approved for concurrent enrollment by the global study manager. * subject with exclusion criteria required by local law.